StevenDavidGoreMD

Oncology • Rockville, MD

Hematologic Oncology

Professor, Medicine (Hematology), Yale School of Medicine

Join to view full profile

Dr. Gore is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Gore's full profile

Already have an account?

Office
9609 Medical Center Drive
Rockville, MD 20850
Phone+1 443-854-1650

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1987 - 1990
University of ChicagoResidency, Internal Medicine, 1984 - 1987
Yale School of MedicineClass of 1984

Certifications & Licensure

MD State Medical License 1987 - 2026
CT State Medical License 2013 - 2020
IL State Medical License 1985 - 1987
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Super Doctor SuperDoctors.com

Clinical Trials

Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Start of enrollment: 2000 May 01
Completed
Phase 1
Phenylbutyrate and Tretinoin in Treating Patients With Hematologic Cancer Start of enrollment: 2000 Dec 01
Completed
Phase 1
Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia Start of enrollment: 2004 Oct 01
Completed
Phase 2
Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Start of enrollment: 2006 Aug 01
Completed
Phase 2
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Start of enrollment: 2009 Jan 29
Active, not recruiting
Phase 3
Trial of High Dose Lenalidomide in Patients With MDS and AML With Trilineage Dysplasia Start of enrollment: 2009 Jul 01
Terminated
Phase 2
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Start of enrollment: 2012 Dec 14
Completed
Phase 1
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2013 Dec 09
Active, not recruiting
Phase 3
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA Start of enrollment: 2013 Dec 01
Completed
Phase 2
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia Start of enrollment: 2014 May 19
Active, not recruiting
Phase 3
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Feb 04
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

93 citations
The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort
Maximilian Stahl, Michelle DeVeaux, Theo de Witte, Judith Neukirchen, Mikkael A. Sekeres
Blood Advances. 2018-07-24
18 citations
A clandestine culprit with critical consequences: Benzene and acute myeloid leukemia
Rory M. Shallis, Julian J Weiss, Nicole C. Deziel, Steven D. Gore
Blood Reviews. 2021-05-01
280 citations
Acute myeloid leukemia, version 3.2019
Martin S. Tallman, Eunice S. Wang, Jessica K. Altman, Frederick R. Appelbaum, Vijaya Raj Bhatt
Journal of the National Comprehensive Cancer Network. 2019-01-01

Abstracts/Posters

Clinical Effectiveness of Hypomethylating Agents (HMAs) and Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Populatio...
Steven D. Gore, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Clinical Outcomes of Older Patients (pts) with Acute Myeloid Leukemia (AML) Receiving Hypomethylating Agents (HMAs): A Large Population-Based Study in the United State...
Steven D. Gore, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Clonal Cytopenias of Undetermined Significance Are Common in Cytopenic Adults Evaluated for MDS in the National MDS Study
Steven D. Gore, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
The Impact of the 2011 European Leukemianet (ELN) Guidelines for Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms on Therapeutic Phlebotomy and ...
Steven D. Gore, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Patterns of Care and Clinical Outcomes with 7+3 Induction Chemotherapy for Patients (pts) with Acute Myeloid Leukemia (AML) in the United States (US): A Large Populati...
Steven D. Gore, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Incidence and Risk Factors of Second Malignancies Among Medicare Beneficiaries with Newly-Diagnosed Philadelphia Chromosome-Negative Classical Myeloproliferative Neopl...
Steven D. Gore, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
The VITAL Trial: Phase II Trial of Vosaroxin and Infusional Cytarabine for Frontline Treatment of acute Myeloid LeukemiaClinically Relevant Abstract
Steven D. Gore, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center Experience
Steven D. Gore, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients with Myelodysplastic Syndromes (MDS): Results of a L...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: An ...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Riding the Wave: Clinical Management of Myeloid Malignancies in an Era of Novel Therapies
60th American Society of Hematology Annual Meeting - 11/30/2018

Press Mentions

Dioxin Exposure from Agent Orange Linked to AML and MDSApril 1st, 2022
Yale Cancer Center Investigators Show Recommended, but Underused Treatment for Rare Blood Cancer Saves LivesNovember 5th, 2018
$Alternative Option to Intensive Chemotherapy for Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)$
Alternative Option to Intensive Chemotherapy for Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)December 6th, 2016
Join now to see all

Grant Support

Targeting Epigenomics In Myeloid NeoplasmsNational Cancer Institute2005–2011
Mechanism Of Combined 'Epigenetic Therapy'In Myeloid MalignanciesNational Cancer Institute2007–2009
Arsenic Trioxide In Primary Curative APL TherapyNational Cancer Institute2004–2008
5-Azacytidine And MS-275 In Myeloid MalignanciesNational Cancer Institute2004–2005
DNA Methyltransferase/Histone Deacetylase InhibitionNational Cancer Institute2000–2002
Clinical Histone Deacetylase Inhibition And RetinoidsNational Cancer Institute2000–2001
Butyric Acid Derivatives In Myeloid MalignanciesNational Cancer Institute1995–1999
Phase I Trial Of Sodium Phenylbutyrate (EL532) In Myelodysplastic PatientsNational Center For Research Resources1997